Phase 2 Breast Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with invasive breast cancer that has been confirmed by a laboratory tissue test, at specific stages involving the tumour and nearby lymph nodes but without spread to distant parts of the body
• People aged between 18 and 70 years old
• People who are generally well enough to carry out everyday activities with little or no limitation (as assessed by a standard medical scale)
• People whose breast cancer tumour has been tested for hormone receptors (ER and PR) and a protein called HER2
• People whose heart is pumping at a normal level (at least 55% efficiency, as measured by a heart scan)
• People whose cancer subtype has been confirmed through a specific type of digital analysis of tumour tissue samples
• People with triple-negative breast cancer whose tumour has been further classified using additional markers (AR, CD8, and FOXC1) (confirm with trial site)
• People who have at least one tumour that can be measured using standard imaging criteria
• People whose blood counts and organ function fall within acceptable ranges — including blood cell levels, liver function, kidney function, and other routine blood tests
• People who are not pregnant or breastfeeding, and who agree to use a medically approved form of contraception throughout the study treatment and for at least 3 months after the last dose
• People who are able to understand the study and are willing to sign a written consent form

Who may not be able to join:

• People who have previously received chemotherapy, hormone therapy, biological therapy, or radiotherapy for any reason
• People with moderate or severe heart disease, as classified by a standard medical grading system (Grade II or above)
• People with a serious active infection or other significant serious illness
• People with a known allergy or sensitivity to the study drug or any of its ingredients
• People who have had another type of cancer in the past 5 years, with the exception of certain treated cervical or skin cancers that are considered fully cured
• People who are pregnant or breastfeeding, or people of childbearing potential who are not willing to use appropriate contraception during the study
• People who have taken part in another clinical trial within 30 days before the first dose of the study drug
• People whom the trial investigators consider unsuitable for the study for any reason

Important: Always verify eligibility with the trial site directly before applying.